Electra Therapeutics
Electra Therapeutics Raises $183 Million in Series C - October 22, 2024
Electra Therapeutics Raises $183 Million in Series C - October 22, 2024
Executive Summary
Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and inflammatory diseases.
Funding Amount: $183 Million
Valuation: Undisclosed
Round Type: Series C
Announced: October 22, 2024
Headquarters: Basel, Switzerland
Category: Biotechnology
About Electra Therapeutics
Electra Therapeutics was founded in 2021 and is headquartered in Basel, Switzerland. The company currently employs 80+ people and operates in the Biotechnology sector.
Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and inflammatory diseases.
Funding Round Details
Investment Amount
Electra Therapeutics successfully raised $183 Million in this Series C funding round, announced in October 22, 2024.
The company has not disclosed its valuation.
Lead Investors & Participants
Nextech (Lead Investor): Healthcare-focused venture capital
EQT Life Sciences (Healthcare Investor): European life sciences investor
Sanofi (Strategic Pharma): Global pharmaceutical company
HBM Healthcare Investments (Healthcare Investor): Life sciences specialist
Mubadala Capital (Sovereign Wealth): UAE sovereign investment fund
OrbiMed (Healthcare VC): Leading healthcare investment firm
Redmile Group (Healthcare Hedge Fund): Healthcare-focused investor
RA Capital Management (Healthcare Investor): Biotech investment firm
Use of Funds
Advancing Phase 2 clinical trials for lead immunology drug candidates, expanding pipeline in autoimmune diseases, and preparing for regulatory submissions.
The capital will enable Electra Therapeutics to:
- Accelerate product development and innovation
- Expand market reach and customer acquisition
- Scale operations and infrastructure
- Strengthen the team with key hires
- Invest in research and development
Key Metrics & Achievements
- Multiple Phase 2 trials ongoing
- Targeting multi-billion dollar immunology market
- Novel mechanism of action in autoimmune diseases
- Strategic partnership with Sanofi
- Potential for first approval in 2026-2027
Business Model
Electra develops and commercializes immunology therapies for autoimmune and inflammatory diseases, with potential for partnerships and licensing deals with major pharma companies.
Market Opportunity & Competition
Competes with AbbVie, Johnson & Johnson, and other biotech companies developing immunology therapies for conditions like rheumatoid arthritis and inflammatory bowel disease.
The Biotechnology market continues to experience rapid growth, with increasing demand from enterprises and consumers. Electra Therapeutics is well-positioned to capitalize on this opportunity with its differentiated technology and strong investor backing.
What This Means for the Industry
This significant funding round demonstrates strong investor confidence in Electra Therapeutics's vision and execution. The $183 Million investment positions the company to:
- Accelerate Innovation: Develop next-generation products and features
- Expand Market Leadership: Capture greater market share in Biotechnology
- Scale Operations: Build infrastructure to support rapid growth
- Attract Top Talent: Recruit world-class engineers, researchers, and business leaders
- Drive Industry Transformation: Shape the future of Biotechnology
Company Background
Founded: 2021
Headquarters: Basel, Switzerland
Employees: 80+
Industry: Biotechnology
Total Funding: $183 Million+ (this round)
Looking Ahead
With this substantial funding, Electra Therapeutics is positioned for continued growth and innovation in the Biotechnology space. The company plans to leverage the capital to expand its market presence, enhance its product offerings, and solidify its position as a leader in the industry.
Investors and industry analysts will be closely watching Electra Therapeutics as it executes on its ambitious growth plans and works to deliver value to customers and shareholders.
About the Investors
Nextech: Healthcare-focused venture capital
EQT Life Sciences: European life sciences investor
Sanofi: Global pharmaceutical company
This funding announcement was verified through official press releases, SEC filings, and credible news sources including Crunchbase, TechCrunch, and Bloomberg.
Last Updated: October 26, 2025
Company Info
Investors (8)
Share
Related Reports
Kailera Therapeutics Raises $400 Million in Series A - October 2024
Kailera Therapeutics announced $400 Million in Series A funding at a Undisclosed valuation. Kailera Therapeutics raised a massive $400 million Series A to develop clinical-stage injectable and oral therapies for chronic weight management and ...
Citius Pharmaceuticals Headquarters - Office Location & Address
Discover Citius Pharmaceuticals's headquarters at 11 Commerce Dr, Cranford, NJ 07016. Critical care therapeutics developer. Learn about the office facilities and work environment.
Chronos Therapeutics Headquarters - Office Location & Address
Discover Chronos Therapeutics's headquarters at Botley Rd, Oxford, OX2 0JD. Chronopharmacology therapeutics developer. Learn about the office facilities and work environment.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free